4 Stocks Dragging In The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 147 points (1.0%) at 15,587 as of Thursday, Feb. 6, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 2,311 issues advancing vs. 626 declining with 152 unchanged.

The Drugs industry currently sits up 0.8% versus the S&P 500, which is up 1.0%. Top gainers within the industry include Biogen Idec ( BIIB), up 1.9%, Shire ( SHPG), up 1.8%, Novo Nordisk A/S ( NVO), up 1.7%, GlaxoSmithKline ( GSK), up 0.9% and Johnson & Johnson ( JNJ), up 0.9%.

TheStreet would like to highlight 4 stocks pushing the industry lower today:

4. Sanofi ( SNY) is one of the companies pushing the Drugs industry lower today. As of noon trading, Sanofi is down $0.88 (-1.8%) to $47.41 on heavy volume. Thus far, 2.0 million shares of Sanofi exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $47.06-$47.50 after having opened the day at $47.08 as compared to the previous trading day's close of $48.29.

Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in Pharmaceuticals, Human Vaccines, and Animal Health segments. Sanofi has a market cap of $129.4 billion and is part of the health care sector. Shares are down 10.0% year-to-date as of the close of trading on Wednesday. Currently there are 2 analysts that rate Sanofi a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Sanofi Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

3. As of noon trading, AstraZeneca ( AZN) is down $1.33 (-2.1%) to $62.17 on average volume. Thus far, 1.2 million shares of AstraZeneca exchanged hands as compared to its average daily volume of 2.2 million shares. The stock has ranged in price between $61.75-$62.28 after having opened the day at $62.14 as compared to the previous trading day's close of $63.50.

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. AstraZeneca has a market cap of $79.2 billion and is part of the health care sector. Shares are up 7.0% year-to-date as of the close of trading on Wednesday. Currently there are 2 analysts that rate AstraZeneca a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full AstraZeneca Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Perrigo Company ( PRGO) is down $5.38 (-3.5%) to $147.90 on heavy volume. Thus far, 1.6 million shares of Perrigo Company exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $144.46-$155.22 after having opened the day at $153.87 as compared to the previous trading day's close of $153.28.

Perrigo Company, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API). Perrigo Company has a market cap of $14.7 billion and is part of the health care sector. Shares are down 0.1% year-to-date as of the close of trading on Wednesday. Currently there are 12 analysts that rate Perrigo Company a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Perrigo Company as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, good cash flow from operations and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Perrigo Company Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Teva Pharmaceutical Industries ( TEVA) is down $0.74 (-1.6%) to $44.65 on average volume. Thus far, 3.9 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 5.9 million shares. The stock has ranged in price between $44.32-$45.85 after having opened the day at $45.43 as compared to the previous trading day's close of $45.39.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $37.6 billion and is part of the health care sector. Shares are up 13.2% year-to-date as of the close of trading on Wednesday. Currently there are 4 analysts that rate Teva Pharmaceutical Industries a buy, 3 analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Teva Pharmaceutical Industries Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null

If you liked this article you might like

Generic Drug Makers Hurt By Latest Federal Government Budget

Generic Drug Makers Hurt By Latest Federal Government Budget

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Investors Are Trying to Figure Out the 'Powell Put'

Investors Are Trying to Figure Out the 'Powell Put'

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know